This combined, with the good clinical safety profile of REG3A (ALF-5755) observed in a phase I study involving healthy volunteers and a phase II study in patients with acute liver failure23,51, are major arguments for translational exploration of REG3A in patients with type 2 diabetes. Here, REG3A is linked to type 2 diabetes mellitus.